Faye M Johnson
M.D. Anderson Cancer Center · MD Anderson Cancer Center Recruiting, Houston, Texas, US 77030 · UT MD Anderson Cancer Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Faye M Johnson as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 00:36 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT04555837 · Alisertib and Pembrolizumab for the Treatment of Patients With Rb-deficient Head and Neck Squamous Cell CancerM.D. Anderson Cancer Center · completed · Head and Neck Squamous Cell Carcinoma, Malignant Solid Neoplasm · principal investigator
- Ph2NCT03740100 · Single-arm Study With Bimiralisib in Patients With HNSCC Harboring NOTCH1 Loss of Function MutationsM.D. Anderson Cancer Center · terminated · HNSCC · principal investigator
- Ph1/Ph2NCT00826449 · Dasatinib and Erlotinib in Non-Small Cell Lung Cancer (NSCLC)M.D. Anderson Cancer Center · completed · Lung Cancer, Non-Small Cell Lung Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 00:36 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Harnessing Aurora kinase inhibition‐induced cell death to enhance immunotherapy in HPV‐driven cancersR01CA248205 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 2020 to 2024 · $352,047 awarded in 2024Same name and institution; not confirmed by an ID
- Targeting head and neck cancer cells and the adverse tumor microenvironment with a novel small-molecule STAT3 inhibitorR01CA269516 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 2022 to 2024 · $410,323 awarded in 2024Same name and institution; not confirmed by an ID
- Targeting Alterations of the NOTCH1 Pathway in Head & Neck Squamous Cell Carcinoma (HNSCC)R01CA235620 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 2019 to 2023 · $637,606 awarded in 2023Same name and institution; not confirmed by an ID
- Targeting c-Src in Head and Neck CancerR01CA143369 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 2010 to 2014 · $242,327 awarded in 2014Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 00:36 UTC. The ranking covers the 200 most relevant of 23 PubMed records, and a shared surname and initials can bring in a namesake. All 23 on PubMed
- 220 citationsRCR 5.2
- Phase II study of dasatinib in patients with advanced non-small-cell lung cancer.J Clin Oncol · 2010145 citationsRCR 3.0
- Pilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck.Clin Cancer Res · 2021135 citationsRCR 7.2
- Phase I Study of LY2606368, a Checkpoint Kinase 1 Inhibitor, in Patients With Advanced Cancer.J Clin Oncol · 2016133 citationsRCR 3.6
- Impact of Neoadjuvant Durvalumab with or without Tremelimumab on CD8+ Tumor Lymphocyte Density, Safety, and Efficacy in Patients with Oropharynx Cancer: CIAO Trial Results.Clin Cancer Res · 2020117 citationsRCR 4.1
- Phase 1 pharmacokinetic and drug-interaction study of dasatinib in patients with advanced solid tumors.Cancer · 201099 citationsRCR 2.8
- Epidermal growth factor receptor expression and gene copy number in the risk of oral cancer.Cancer Prev Res (Phila) · 201097 citationsRCR 2.4
- 94 citationsRCR 4.0
- ISA101 and nivolumab for HPV-16+ cancer: updated clinical efficacy and immune correlates of response.J Immunother Cancer · 202291 citationsRCR 6.3
- 87 citationsRCR 2.2